查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867493

微生物组药物：全球市场份额和排名、总收入和需求预测（2025-2031年）

Microbiome Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 157 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球微生物组药物市场预计在 2024 年达到 5.68 亿美元，预计到 2031 年将达到 32.96 亿美元，在 2025 年至 2031 年的预测期内，复合年增长率将达到 30.1%。

微生物组药物是基于人体共生微生物群及其代谢物开发的新型疗法。这些疗法包括活体治疗产品（LBPs）、微生物群衍生代谢物、合成微生物製剂和标靶微生物组的小分子药物。透过调节肠道、皮肤和呼吸道的宿主微生态环境，这些治疗方法旨在恢復免疫平衡、调节代谢，并治疗多种疾病，包括感染疾病、发炎性肠道疾病、代谢紊乱、神经精神疾病和癌症。随着微生物组科学和合成生物学的快速突破，微生物组药物正成为精准医疗的核心支柱，将治疗模式从“杀灭微生物”转变为“利用微生物”，从而实现系统性治疗效果。

随着精准医疗理念在全球范围内不断发展，微生物组药物正迅速崛起，成为生物製药创新领域的新兴战略前沿。多个国家的监管机构已为基于活体微生物群的产品设立了专门的审批途径，加速了其临床应用。根据公司年报显示，多个处于III期临床试验阶段的候选药物即将进入商业化阶段，预示市场即将迎来转捩点。同时，合成生物学的进步使得建构具有稳定表达平台的工程化微生物疗法成为可能，将微生物疗法从粪便移植转变为标准化药物。在慢性病、免疫系统疾病和肿瘤治疗领域日益增长的需求驱动下，全球投资和研发资源正集中于此变革性领域。

儘管微生物组药物具有变革性潜力，但其应用仍处于早期阶段，面临技术和监管方面的许多不确定性。真实世界临床数据显示，部分早期产品有较高的患者间差异和疗效不一致的问题，这给临床标准化带来了挑战。活体生物製药的生产、低温运输物流和品管要求构成了很高的技术壁垒，尤其是在规模化生产方面。此外，许多地区不完善的健保体系和临床资金筹措机制也阻碍了其在短期内广泛市场渗透。

在需求方面，对宿主-微生物组相互作用的深入了解正推动着从「补充益生菌」到「介入性处方药」的转变。医生们对微生物组的治疗方法越来越感兴趣，尤其是在难治性困难梭状芽孢桿菌传染病、溃疡性大肠炎、泛自闭症障碍和第2型糖尿病患者。领先的医院正与製药公司合作进行共同开发和真实世界研究，从而促进从学术试验到常规临床应用的过渡。随着越来越多的候选药物进入关键测试阶段，微生物组药物有望在全球处方药市场中占据一个独特且极具潜力的细分市场。

本报告旨在对全球微生物组药物市场进行全面分析，重点关注总收入、市场份额和主要企业的排名，并按地区/国家、类型和适应症对微生物组药物进行分析。

本报告以收益为准，以 2024 年为基准年，对微生物组药物市场规模、估算和预测进行了阐述，并包含了 2020 年至 2031 年的历史数据和预测数据。报告运用定量和定性分析，帮助读者制定业务/成长策略，评估市场竞争格局，分析自身在当前市场中的地位，并就微生物组药物做出明智的商业决策。

市场区隔

公司

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Finch Therapeutics
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • Ferring
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Vedanta Biosciences
  • Metabogen

按类型分類的细分市场

  • 口服剂型
  • 肠溶胶囊

症状片段

  • 胃肠道疾病
  • 自体免疫疾病
  • 糖尿病
  • 癌症
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Microbiome Drugs was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3296 million by 2031 with a CAGR of 30.1% during the forecast period 2025-2031.

Microbiome Drugs refer to a new class of therapeutic agents developed based on human commensal microbiota and their metabolites. These include live biotherapeutic products (LBPs), microbiota-derived metabolites, synthetic microbial formulations, and microbiome-targeted small molecule drugs. By modulating the host's microecological environment-such as the gut, skin, or respiratory tract-these therapies aim to restore immune balance, regulate metabolism, and treat a broad spectrum of diseases including infectious conditions, inflammatory bowel diseases, metabolic disorders, neuropsychiatric illnesses, and cancers. As breakthroughs in microbiome science and synthetic biology continue to accelerate, microbiome drugs are emerging as a core pillar of precision medicine-transforming treatment paradigms from "killing microbes" to "leveraging microbes" for systemic therapeutic benefit.

As the concept of precision medicine continues to evolve globally, microbiome drugs are rapidly emerging as a new strategic frontier in biopharmaceutical innovation. Regulatory authorities in multiple countries have established dedicated review pathways for live microbiome-based products, accelerating clinical translation. According to annual reports from companies several Phase III candidates are approaching commercialization, signaling an imminent market inflection point. Meanwhile, advances in synthetic biology are enabling engineered microbial therapeutics with stable expression platforms, transforming microbiota therapies from fecal transplants into standardized pharmaceuticals. With chronic diseases, immune disorders, and oncology driving demand, global investment and R&D resources are converging toward this transformative sector.

Despite their disruptive potential, microbiome drugs remain in the early adoption phase, facing both technological and regulatory uncertainty. Real-world data reveal high inter-patient variability and inconsistent efficacy in some early-stage products, posing challenges for clinical standardization. Manufacturing, cold-chain logistics, and quality control requirements for live biotherapeutics impose high technical barriers, particularly in scaling up production. In addition, reimbursement frameworks and clinical funding mechanisms are still underdeveloped in many regions, slowing broad market penetration in the short term.

On the demand side, deeper insights into host-microbiome interactions are driving a shift from "supplemental probiotics" to "interventional prescription drugs." Physicians are increasingly open to microbiome-based therapies, especially for patients with refractory Clostridium difficile infections, ulcerative colitis, autism spectrum disorders, and type 2 diabetes. Leading hospitals are partnering with pharma companies to conduct joint development and real-world studies, fostering a transition from academic trials to routine clinical use. As more candidates reach critical trial milestones, microbiome drugs are poised to establish a distinct and high-potential segment within the global prescription drug market.

This report aims to provide a comprehensive presentation of the global market for Microbiome Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Microbiome Drugs by region & country, by Type, and by Symptom.

The Microbiome Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Microbiome Drugs.

Market Segmentation

By Company

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Finch Therapeutics
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • Ferring
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Vedanta Biosciences
  • Metabogen

Segment by Type

  • Oral Dosage Form
  • Enteric Capsules

Segment by Symptom

  • Gastrointestinal Disorders
  • Autoimmune Disorders
  • Diabetes
  • Cancer
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Microbiome Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Symptom, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Microbiome Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Microbiome Drugs in country level. It provides sigmate data by Type, and by Symptom for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Microbiome Drugs Product Introduction
  • 1.2 Global Microbiome Drugs Market Size Forecast (2020-2031)
  • 1.3 Microbiome Drugs Market Trends & Drivers
    • 1.3.1 Microbiome Drugs Industry Trends
    • 1.3.2 Microbiome Drugs Market Drivers & Opportunity
    • 1.3.3 Microbiome Drugs Market Challenges
    • 1.3.4 Microbiome Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Microbiome Drugs Players Revenue Ranking (2024)
  • 2.2 Global Microbiome Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies Microbiome Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Microbiome Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Microbiome Drugs
  • 2.6 Microbiome Drugs Market Competitive Analysis
    • 2.6.1 Microbiome Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Microbiome Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Oral Dosage Form
    • 3.1.2 Enteric Capsules
  • 3.2 Global Microbiome Drugs Sales Value by Type
    • 3.2.1 Global Microbiome Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Microbiome Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Microbiome Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Symptom

  • 4.1 Introduction by Symptom
    • 4.1.1 Gastrointestinal Disorders
    • 4.1.2 Autoimmune Disorders
    • 4.1.3 Diabetes
    • 4.1.4 Cancer
    • 4.1.5 Others
  • 4.2 Global Microbiome Drugs Sales Value by Symptom
    • 4.2.1 Global Microbiome Drugs Sales Value by Symptom (2020 VS 2024 VS 2031)
    • 4.2.2 Global Microbiome Drugs Sales Value, by Symptom (2020-2031)
    • 4.2.3 Global Microbiome Drugs Sales Value, by Symptom (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Microbiome Drugs Sales Value by Region
    • 5.1.1 Global Microbiome Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Microbiome Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Microbiome Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Microbiome Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Microbiome Drugs Sales Value, 2020-2031
    • 5.2.2 North America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Microbiome Drugs Sales Value, 2020-2031
    • 5.3.2 Europe Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Microbiome Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Microbiome Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Microbiome Drugs Sales Value, 2020-2031
    • 5.5.2 South America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Microbiome Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Microbiome Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Microbiome Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Microbiome Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Microbiome Drugs Sales Value, 2020-2031
    • 6.3.2 United States Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Microbiome Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Microbiome Drugs Sales Value, 2020-2031
    • 6.5.2 China Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Microbiome Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Microbiome Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Microbiome Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Microbiome Drugs Sales Value by Symptom, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Microbiome Drugs Sales Value, 2020-2031
    • 6.9.2 India Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Microbiome Drugs Sales Value by Symptom, 2024 VS 2031

7 Company Profiles

  • 7.1 Seres Therapeutics
    • 7.1.1 Seres Therapeutics Profile
    • 7.1.2 Seres Therapeutics Main Business
    • 7.1.3 Seres Therapeutics Microbiome Drugs Products, Services and Solutions
    • 7.1.4 Seres Therapeutics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Seres Therapeutics Recent Developments
  • 7.2 Assembly Biosciences
    • 7.2.1 Assembly Biosciences Profile
    • 7.2.2 Assembly Biosciences Main Business
    • 7.2.3 Assembly Biosciences Microbiome Drugs Products, Services and Solutions
    • 7.2.4 Assembly Biosciences Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Assembly Biosciences Recent Developments
  • 7.3 Synthetic Biologics
    • 7.3.1 Synthetic Biologics Profile
    • 7.3.2 Synthetic Biologics Main Business
    • 7.3.3 Synthetic Biologics Microbiome Drugs Products, Services and Solutions
    • 7.3.4 Synthetic Biologics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Synthetic Biologics Recent Developments
  • 7.4 Finch Therapeutics
    • 7.4.1 Finch Therapeutics Profile
    • 7.4.2 Finch Therapeutics Main Business
    • 7.4.3 Finch Therapeutics Microbiome Drugs Products, Services and Solutions
    • 7.4.4 Finch Therapeutics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Finch Therapeutics Recent Developments
  • 7.5 PureTech
    • 7.5.1 PureTech Profile
    • 7.5.2 PureTech Main Business
    • 7.5.3 PureTech Microbiome Drugs Products, Services and Solutions
    • 7.5.4 PureTech Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 PureTech Recent Developments
  • 7.6 Synlogic
    • 7.6.1 Synlogic Profile
    • 7.6.2 Synlogic Main Business
    • 7.6.3 Synlogic Microbiome Drugs Products, Services and Solutions
    • 7.6.4 Synlogic Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Synlogic Recent Developments
  • 7.7 Enterome BioScience
    • 7.7.1 Enterome BioScience Profile
    • 7.7.2 Enterome BioScience Main Business
    • 7.7.3 Enterome BioScience Microbiome Drugs Products, Services and Solutions
    • 7.7.4 Enterome BioScience Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Enterome BioScience Recent Developments
  • 7.8 4D Pharma
    • 7.8.1 4D Pharma Profile
    • 7.8.2 4D Pharma Main Business
    • 7.8.3 4D Pharma Microbiome Drugs Products, Services and Solutions
    • 7.8.4 4D Pharma Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.8.5 4D Pharma Recent Developments
  • 7.9 Second Genome
    • 7.9.1 Second Genome Profile
    • 7.9.2 Second Genome Main Business
    • 7.9.3 Second Genome Microbiome Drugs Products, Services and Solutions
    • 7.9.4 Second Genome Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Second Genome Recent Developments
  • 7.10 Ferring
    • 7.10.1 Ferring Profile
    • 7.10.2 Ferring Main Business
    • 7.10.3 Ferring Microbiome Drugs Products, Services and Solutions
    • 7.10.4 Ferring Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Ferring Recent Developments
  • 7.11 C3 Jian
    • 7.11.1 C3 Jian Profile
    • 7.11.2 C3 Jian Main Business
    • 7.11.3 C3 Jian Microbiome Drugs Products, Services and Solutions
    • 7.11.4 C3 Jian Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.11.5 C3 Jian Recent Developments
  • 7.12 Rebiotix
    • 7.12.1 Rebiotix Profile
    • 7.12.2 Rebiotix Main Business
    • 7.12.3 Rebiotix Microbiome Drugs Products, Services and Solutions
    • 7.12.4 Rebiotix Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Rebiotix Recent Developments
  • 7.13 MicroBiome Therapeutics LLC
    • 7.13.1 MicroBiome Therapeutics LLC Profile
    • 7.13.2 MicroBiome Therapeutics LLC Main Business
    • 7.13.3 MicroBiome Therapeutics LLC Microbiome Drugs Products, Services and Solutions
    • 7.13.4 MicroBiome Therapeutics LLC Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.13.5 MicroBiome Therapeutics LLC Recent Developments
  • 7.14 Metabiomics
    • 7.14.1 Metabiomics Profile
    • 7.14.2 Metabiomics Main Business
    • 7.14.3 Metabiomics Microbiome Drugs Products, Services and Solutions
    • 7.14.4 Metabiomics Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Metabiomics Recent Developments
  • 7.15 Ritter Pharmaceuticals
    • 7.15.1 Ritter Pharmaceuticals Profile
    • 7.15.2 Ritter Pharmaceuticals Main Business
    • 7.15.3 Ritter Pharmaceuticals Microbiome Drugs Products, Services and Solutions
    • 7.15.4 Ritter Pharmaceuticals Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Ritter Pharmaceuticals Recent Developments
  • 7.16 Symberix
    • 7.16.1 Symberix Profile
    • 7.16.2 Symberix Main Business
    • 7.16.3 Symberix Microbiome Drugs Products, Services and Solutions
    • 7.16.4 Symberix Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.16.5 Symberix Recent Developments
  • 7.17 OpenBiome
    • 7.17.1 OpenBiome Profile
    • 7.17.2 OpenBiome Main Business
    • 7.17.3 OpenBiome Microbiome Drugs Products, Services and Solutions
    • 7.17.4 OpenBiome Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.17.5 OpenBiome Recent Developments
  • 7.18 Azitra
    • 7.18.1 Azitra Profile
    • 7.18.2 Azitra Main Business
    • 7.18.3 Azitra Microbiome Drugs Products, Services and Solutions
    • 7.18.4 Azitra Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.18.5 Azitra Recent Developments
  • 7.19 Symbiotix Biotherapies
    • 7.19.1 Symbiotix Biotherapies Profile
    • 7.19.2 Symbiotix Biotherapies Main Business
    • 7.19.3 Symbiotix Biotherapies Microbiome Drugs Products, Services and Solutions
    • 7.19.4 Symbiotix Biotherapies Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.19.5 Symbiotix Biotherapies Recent Developments
  • 7.20 Vedanta Biosciences
    • 7.20.1 Vedanta Biosciences Profile
    • 7.20.2 Vedanta Biosciences Main Business
    • 7.20.3 Vedanta Biosciences Microbiome Drugs Products, Services and Solutions
    • 7.20.4 Vedanta Biosciences Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.20.5 Vedanta Biosciences Recent Developments
  • 7.21 Metabogen
    • 7.21.1 Metabogen Profile
    • 7.21.2 Metabogen Main Business
    • 7.21.3 Metabogen Microbiome Drugs Products, Services and Solutions
    • 7.21.4 Metabogen Microbiome Drugs Revenue (US$ Million) & (2020-2025)
    • 7.21.5 Metabogen Recent Developments

8 Industry Chain Analysis

  • 8.1 Microbiome Drugs Industrial Chain
  • 8.2 Microbiome Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Microbiome Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Microbiome Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Microbiome Drugs Market Trends
  • Table 2. Microbiome Drugs Market Drivers & Opportunity
  • Table 3. Microbiome Drugs Market Challenges
  • Table 4. Microbiome Drugs Market Restraints
  • Table 5. Global Microbiome Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Microbiome Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Microbiome Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Microbiome Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Microbiome Drugs
  • Table 10. Global Microbiome Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Microbiome Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Microbiome Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Microbiome Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Microbiome Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Microbiome Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Microbiome Drugs Sales Value by Symptom: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Microbiome Drugs Sales Value by Symptom (2020-2025) & (US$ Million)
  • Table 20. Global Microbiome Drugs Sales Value by Symptom (2026-2031) & (US$ Million)
  • Table 21. Global Microbiome Drugs Sales Market Share in Value by Symptom (2020-2025)
  • Table 22. Global Microbiome Drugs Sales Market Share in Value by Symptom (2026-2031)
  • Table 23. Global Microbiome Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Microbiome Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Microbiome Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Microbiome Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Microbiome Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Microbiome Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Microbiome Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Microbiome Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Seres Therapeutics Basic Information List
  • Table 32. Seres Therapeutics Description and Business Overview
  • Table 33. Seres Therapeutics Microbiome Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Microbiome Drugs Business of Seres Therapeutics (2020-2025)
  • Table 35. Seres Therapeutics Recent Developments
  • Table 36. Assembly Biosciences Basic Information List
  • Table 37. Assembly Biosciences Description and Business Overview
  • Table 38. Assembly Biosciences Microbiome Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Microbiome Drugs Business of Assembly Biosciences (2020-2025)
  • Table 40. Assembly Biosciences Recent Developments
  • Table 41. Synthetic Biologics Basic Information List
  • Table 42. Synthetic Biologics Description and Business Overview
  • Table 43. Synthetic Biologics Microbiome Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Microbiome Drugs Business of Synthetic Biologics (2020-2025)
  • Table 45. Synthetic Biologics Recent Developments
  • Table 46. Finch Therapeutics Basic Information List
  • Table 47. Finch Therapeutics Description and Business Overview
  • Table 48. Finch Therapeutics Microbiome Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Microbiome Drugs Business of Finch Therapeutics (2020-2025)
  • Table 50. Finch Therapeutics Recent Developments
  • Table 51. PureTech Basic Information List
  • Table 52. PureTech Description and Business Overview
  • Table 53. PureTech Microbiome Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Microbiome Drugs Business of PureTech (2020-2025)
  • Table 55. PureTech Recent Developments
  • Table 56. Synlogic Basic Information List
  • Table 57. Synlogic Description and Business Overview
  • Table 58. Synlogic Microbiome Drugs Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Microbiome Drugs Business of Synlogic (2020-2025)
  • Table 60. Synlogic Recent Developments
  • Table 61. Enterome BioScience Basic Information List
  • Table 62. Enterome BioScience Description and Business Overview
  • Table 63. Enterome BioScience Microbiome Drugs Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Microbiome Drugs Business of Enterome BioScience (2020-2025)
  • Table 65. Enterome BioScience Recent Developments
  • Table 66. 4D Pharma Basic Information List
  • Table 67. 4D Pharma Description and Business Overview
  • Table 68. 4D Pharma Microbiome Drugs Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Microbiome Drugs Business of 4D Pharma (2020-2025)
  • Table 70. 4D Pharma Recent Developments
  • Table 71. Second Genome Basic Information List
  • Table 72. Second Genome Description and Business Overview
  • Table 73. Second Genome Microbiome Drugs Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Microbiome Drugs Business of Second Genome (2020-2025)
  • Table 75. Second Genome Recent Developments
  • Table 76. Ferring Basic Information List
  • Table 77. Ferring Description and Business Overview
  • Table 78. Ferring Microbiome Drugs Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Microbiome Drugs Business of Ferring (2020-2025)
  • Table 80. Ferring Recent Developments
  • Table 81. C3 Jian Basic Information List
  • Table 82. C3 Jian Description and Business Overview
  • Table 83. C3 Jian Microbiome Drugs Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Microbiome Drugs Business of C3 Jian (2020-2025)
  • Table 85. C3 Jian Recent Developments
  • Table 86. Rebiotix Basic Information List
  • Table 87. Rebiotix Description and Business Overview
  • Table 88. Rebiotix Microbiome Drugs Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Microbiome Drugs Business of Rebiotix (2020-2025)
  • Table 90. Rebiotix Recent Developments
  • Table 91. MicroBiome Therapeutics LLC Basic Information List
  • Table 92. MicroBiome Therapeutics LLC Description and Business Overview
  • Table 93. MicroBiome Therapeutics LLC Microbiome Drugs Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Microbiome Drugs Business of MicroBiome Therapeutics LLC (2020-2025)
  • Table 95. MicroBiome Therapeutics LLC Recent Developments
  • Table 96. Metabiomics Basic Information List
  • Table 97. Metabiomics Description and Business Overview
  • Table 98. Metabiomics Microbiome Drugs Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Microbiome Drugs Business of Metabiomics (2020-2025)
  • Table 100. Metabiomics Recent Developments
  • Table 101. Ritter Pharmaceuticals Basic Information List
  • Table 102. Ritter Pharmaceuticals Description and Business Overview
  • Table 103. Ritter Pharmaceuticals Microbiome Drugs Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Microbiome Drugs Business of Ritter Pharmaceuticals (2020-2025)
  • Table 105. Ritter Pharmaceuticals Recent Developments
  • Table 106. Symberix Basic Information List
  • Table 107. Symberix Description and Business Overview
  • Table 108. Symberix Microbiome Drugs Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Microbiome Drugs Business of Symberix (2020-2025)
  • Table 110. Symberix Recent Developments
  • Table 111. OpenBiome Basic Information List
  • Table 112. OpenBiome Description and Business Overview
  • Table 113. OpenBiome Microbiome Drugs Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Microbiome Drugs Business of OpenBiome (2020-2025)
  • Table 115. OpenBiome Recent Developments
  • Table 116. Azitra Basic Information List
  • Table 117. Azitra Description and Business Overview
  • Table 118. Azitra Microbiome Drugs Products, Services and Solutions
  • Table 119. Revenue (US$ Million) in Microbiome Drugs Business of Azitra (2020-2025)
  • Table 120. Azitra Recent Developments
  • Table 121. Symbiotix Biotherapies Basic Information List
  • Table 122. Symbiotix Biotherapies Description and Business Overview
  • Table 123. Symbiotix Biotherapies Microbiome Drugs Products, Services and Solutions
  • Table 124. Revenue (US$ Million) in Microbiome Drugs Business of Symbiotix Biotherapies (2020-2025)
  • Table 125. Symbiotix Biotherapies Recent Developments
  • Table 126. Vedanta Biosciences Basic Information List
  • Table 127. Vedanta Biosciences Description and Business Overview
  • Table 128. Vedanta Biosciences Microbiome Drugs Products, Services and Solutions
  • Table 129. Revenue (US$ Million) in Microbiome Drugs Business of Vedanta Biosciences (2020-2025)
  • Table 130. Vedanta Biosciences Recent Developments
  • Table 131. Metabogen Basic Information List
  • Table 132. Metabogen Description and Business Overview
  • Table 133. Metabogen Microbiome Drugs Products, Services and Solutions
  • Table 134. Revenue (US$ Million) in Microbiome Drugs Business of Metabogen (2020-2025)
  • Table 135. Metabogen Recent Developments
  • Table 136. Key Raw Materials Lists
  • Table 137. Raw Materials Key Suppliers Lists
  • Table 138. Microbiome Drugs Downstream Customers
  • Table 139. Microbiome Drugs Distributors List
  • Table 140. Research Programs/Design for This Report
  • Table 141. Key Data Information from Secondary Sources
  • Table 142. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Microbiome Drugs Product Picture
  • Figure 2. Global Microbiome Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Microbiome Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Microbiome Drugs Report Years Considered
  • Figure 5. Global Microbiome Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Microbiome Drugs Revenue in 2024
  • Figure 7. Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Oral Dosage Form Picture
  • Figure 9. Enteric Capsules Picture
  • Figure 10. Global Microbiome Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Microbiome Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Gastrointestinal Disorders
  • Figure 13. Product Picture of Autoimmune Disorders
  • Figure 14. Product Picture of Diabetes
  • Figure 15. Product Picture of Cancer
  • Figure 16. Product Picture of Others
  • Figure 17. Global Microbiome Drugs Sales Value by Symptom (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Microbiome Drugs Sales Value Market Share by Symptom, 2024 & 2031
  • Figure 19. North America Microbiome Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Microbiome Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Microbiome Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Microbiome Drugs Sales Value (%), (2020-2031)
  • Figure 30. United States Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 33. Europe Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 36. China Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 39. Japan Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 42. South Korea Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 45. Southeast Asia Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 48. India Microbiome Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Microbiome Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Microbiome Drugs Sales Value by Symptom (%), 2024 VS 2031
  • Figure 51. Microbiome Drugs Industrial Chain
  • Figure 52. Microbiome Drugs Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed